Katsunobu Hagihara

Summary

Affiliation: Daiichi Sankyo Co
Country: Japan

Publications

  1. ncbi The intestine as an important contributor to prasugrel active metabolite formation in vivo
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, Japan
    Drug Metab Dispos 39:565-70. 2011
  2. ncbi Glutaredoxin is involved in the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo 140 8710, Japan
    Drug Metab Dispos 40:1854-9. 2012
  3. ncbi Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats
    K Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Tokyo, Japan
    Xenobiotica 37:788-801. 2007
  4. ncbi Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Japan
    Drug Metab Pharmacokinet 23:412-20. 2008
  5. ncbi Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs
    K Hagihara
    Daiichi Sankyo Co Ltd, Tokyo, Japan
    Xenobiotica 39:218-26. 2009
  6. ncbi A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 37:2145-52. 2009
  7. ncbi Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 39:208-14. 2011
  8. ncbi Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite
    Katsunobu Hagihara
    Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 38:898-904. 2010
  9. ncbi Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
    Miho Kazui
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 38:92-9. 2010
  10. ncbi Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel
    Yumi Nishiya
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo 140 8710, Japan
    Drug Metab Dispos 37:589-93. 2009

Detail Information

Publications12

  1. ncbi The intestine as an important contributor to prasugrel active metabolite formation in vivo
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, Japan
    Drug Metab Dispos 39:565-70. 2011
    ..In conclusion, this is the first report to directly demonstrate that the conversion of prasugrel to R-138727 in the intestine is comparable to that converted in the liver of dogs...
  2. ncbi Glutaredoxin is involved in the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo 140 8710, Japan
    Drug Metab Dispos 40:1854-9. 2012
    ..9 ± 7.5 μl · min⁻¹ · μg⁻¹. In conclusion, we found that human glutaredoxin is a main contributor to the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate in human liver...
  3. ncbi Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats
    K Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Tokyo, Japan
    Xenobiotica 37:788-801. 2007
    ..1%), which was reabsorbed moderately (62.4%). The results showed that orally administered prasugrel was rapidly and fully absorbed and efficiently converted to the active metabolite with no marked distribution in a particular tissue...
  4. ncbi Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Japan
    Drug Metab Pharmacokinet 23:412-20. 2008
    ..The active metabolites of clopidogrel and prasugrel and clopidogrel acid metabolite also did not affect the activities of the P450s examined...
  5. ncbi Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs
    K Hagihara
    Daiichi Sankyo Co Ltd, Tokyo, Japan
    Xenobiotica 39:218-26. 2009
    ..In conclusion, the extent of in vivo formation of the thiolactone and the active metabolite of prasugrel was greater than for clopidogrel's thiolactone and active metabolite...
  6. ncbi A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 37:2145-52. 2009
    ....
  7. ncbi Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel
    Katsunobu Hagihara
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 39:208-14. 2011
    ..This study is the first in vitro observation indicating that glutaredoxin and thioredoxin in human liver are active in reducing the mixed disulfide formed between xenobiotics and glutathione...
  8. ncbi Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite
    Katsunobu Hagihara
    Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 38:898-904. 2010
    ....
  9. ncbi Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
    Miho Kazui
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 38:92-9. 2010
    ..These results help explain the role of genetic polymorphism of CYP2C19 and also the effect of potent CYP3A inhibitors on the pharmacokinetics and pharmacodynamics of clopidogrel in humans and on clinical outcomes...
  10. ncbi Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel
    Yumi Nishiya
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo 140 8710, Japan
    Drug Metab Dispos 37:589-93. 2009
    ..In conclusion, ticlopidine, its thiolactone metabolite, and clopidogrel were more potent mechanism-based inhibitors of CYP2B6 than the thiolactone metabolite of prasugrel...
  11. ncbi Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel
    Y Nishiya
    Department of Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, Tokyo, Japan
    Xenobiotica 39:836-43. 2009
    ..In conclusion, clopidogrel is potent mechanism-based inhibitors of CYP2C19 as well as ticlopidine, whereas prasugrel did not inactivate CYP2C19. Administration of prasugrel would not cause a clinically relevant interaction with CYP2C19...
  12. ncbi The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
    A Sugidachi
    Pharmacology and Molecular Biology Research Laboratories, Sankyo Co, Ltd, Shinagawa ku, Tokyo, Japan
    J Thromb Haemost 5:1545-51. 2007
    ..Previous studies have shown that the antiplatelet potency of prasugrel is at least 10 times higher than that of clopidogrel in rats and humans, but the mechanism of its higher potency has not yet been fully elucidated...